The impact of menopausal hormone therapy and oral contraceptives on melanoma risk: a review of findings

Tamimi, Pegah; Ghaderi, Aliasghar; Tamimi, Parham

Volume 16, Issue 2 (Volume 16, No 2 2025) jdc 2025, 16(2): 130-136 | Back to browse issues page

Mendeley

Zotero

RefWorks

Tamimi P, Ghaderi A, Tamimi P. The impact of menopausal hormone therapy and oral contraceptives on melanoma risk: a review of findings. jdc 2025; 16 (2) :130-136
URL: http://jdc.tums.ac.ir/article-1-5798-en.html

The impact of menopausal hormone therapy and oral contraceptives on melanoma risk: a review of findings

Pegah Tamimi ^*¹

, Aliasghar Ghaderi²

, Parham Tamimi³

1- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran , pegahtamimi.md@gmail.com
2- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: (849 Views)

This article reviews the impact of Menopausal Hormone Therapy (MHT) and oral contraceptives on melanoma risk. While some studies suggest an association between MHT and melanoma, conflicting evidence exists, including differences in drug formulations across countries, age at the start of treatment, and duration of use. Most studies have found no connection between oral contraceptive use and an increased melanoma risk, though environmental factors like sun exposure may play a role in this relationship. Overall, it appears that women should continue hormone therapy based on their healthcare provider’s advice, without specific concerns about melanoma risk.

Keywords: melanoma, menopausal hormone therapy, oral contraceptives, estrogen, progestin

Full-Text [PDF 429 kb] (345 Downloads)

Type of Study: Review | Subject: General